ALEC

Alector, Inc.

Fundamental data last updated:June 4, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

08/06/2026

Business Summary

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

 


Analyze ALEC on TradingView

VALUATION

P/E

-1.88

Market Cap ($M USD)

$237.04M

Forward P/E

-5.66

PEG

-0.08

PRICE TO SALES

12.87

PRICE TO BOOK

22.74

EV / EBITDA

-1.56

5-Year Average P/E

Free Cash Flow Yield

-73.07%

DCF Value

$-0.21

Graham Number

N/A

Price to FCF

-1.37

EV to FCF

-1.12

Earnings Yield

-53.11%

FCF Yield

-73.07%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.13

Next Year EPS Growth Estimate

-$0.38

Next Year Revenue Growth Estimate

$1.91B

Return on Equity (ROE)

-295.17%

FREE CASH FLOW

Operating Margin

-741.33%

Debt-to-Equity

1.18

Piotroski F-Score

1

Altman Z-Score

-6.07

Return on Invested Capital (ROIC)

-68.63%

Current Ratio

5.25

Quick Ratio

5.25

Net Debt to EBITDA

0.34

Interest Coverage

0.00

Gross Profit margin

88.68%

FCF PER SHARE

$-1.57

REVENUE PER SHARE

$0.17

Analyze ALEC on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to have priced Alector, Inc. with a heavy dose of skepticism. With a Forward P/E of -5.53 and an Altman Z-score of -6.00, the company is signaling distress, suggesting significant financial instability. The Earnings Yield of -53.99% further underscores the lack of profitability, while the DCF Value indicates the stock traded well above its intrinsic worth. These metrics paint a picture of a company struggling to find its footing, with the market potentially overestimating its future prospects.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Alector is positioned at the forefront of integrating AI and modern technology into healthcare solutions. The industry's rapid evolution towards personalized medicine and AI-driven diagnostics could offer Alector opportunities to innovate and adapt. However, the company's current financial metrics suggest it may face challenges in capitalizing on these technological shifts.

The Bull Case

For the optimistic investor, Alector's high Current Ratio of 5.25 indicates strong liquidity, providing a buffer against short-term liabilities. Despite a negative ROIC of -63.50%, the company's ability to maintain a Gross Profit Margin of 76.42% suggests some pricing power in its niche market. The low Piotroski F-Score of 1 is concerning, but the potential for explosive sales growth next year could entice those willing to bet on a turnaround.

The Bear Case

Alector's structural weaknesses are glaring. The Price/Book ratio of 22.37 and Price/Sales of 12.66 highlight a valuation that is extended relative to its fundamentals. With an Operating Margin of -685.95% and a negative FCF Yield of -74.29%, the company is hemorrhaging cash, raising red flags about its long-term viability. The stock's proximity to its 52-week high further suggests it may be technically overextended, making it a risky proposition for cautious investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$2.00

Institutional Ownership %

1-Year Beta

0.65

Insider Buying % (6 Mo)

Distance to 52-Week High

59.25%

Distance to 52-Week Low

48.95%

EARNINGS SURPRISE %

40.00%

50-DAY SMA

$2.30

200-DAY SMA

$2.12

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.